Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib

被引：0
|
作者：
Kazuo, K.
Morrison, L. E.
Kimura, H.
Sone, T.
Araya, T.
Tamori, S.
Tanbo, Y.
Fujimura, M.
Speake, G.
Holloway, B. R.
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa, Japan
[2] Abbott Mol Inc, Des Plaines, IL USA
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7599
引用
收藏
页数：2
相关论文
共 50 条
  • [31] HGF/MET rescues Gefitinib treated non-small cell lung cancer cells carrying an activating EGFR mutation
    Sun, Mark Y.
    Bachleitner-Hofmann, Thomas
    Chen, Chin-Tung
    Solit, David B.
    Weiser, Martin R.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 207 (03) : S100 - S101
  • [32] A comparison of gefitinib for advanced non-small cell lung cancer patients with different EGFR mutation types.
    Zhang, Haijun
    Patel, Nishant
    Wu, Pingping
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations
    Ichihara, Eiki
    Hotta, Katsuyuki
    Takigawa, Nagio
    Kudo, Kenichiro
    Kato, Yuka
    Hondaa, Yoshihiro
    Hayakawa, Hiromi
    Minami, Daisuke
    Sato, Akiko
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER, 2013, 81 (03) : 435 - 439
  • [34] Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation
    Benchakroun, N.
    Minoungou, N.
    Bouchbika, Z.
    Jouhadi, H.
    Tawfik, N.
    Sahraoui, S.
    Benider, A.
    Acharki, A.
    Lemzah, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S953 - S953
  • [35] Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations.
    Sunaga, N.
    Yanagitani, N.
    Kaira, K.
    Tomizawa, Y.
    Iijima, H.
    Otani, Y.
    Tanaka, S.
    Suga, T.
    Dobashi, K.
    Mori, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 409S - 409S
  • [36] Longitudinal tumor dynamic modeling in non-small cell lung cancer (NSCLC) patients treated with gefitinib
    Xu, Hongmei
    Zhou, Diansong
    Tong, Xiao
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S39 - S39
  • [37] Gefitinib Combined With Stereotactic Radiosurgery in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
    Wang, Zhen
    Zhu, Xi-Xu
    Wu, Xin-Hu
    Li, Bing
    Shen, Tian-Ze
    Kong, Qing-Tao
    Li, Jing
    Liu, Zhi-Bing
    Jiang, Wan-Rong
    Wang, Yang
    Hou, Bo
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 148 - 153
  • [38] Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations
    Morita, Satoshi
    Okamoto, Isamu
    Kobayashi, Kunihiko
    Yamazaki, Koichi
    Asahina, Hajime
    Inoue, Akira
    Hagiwara, Koichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Hida, Toyoaki
    Yoshida, Kimihide
    Hirashima, Tomonori
    Yasumoto, Kosei
    Sugio, Kenji
    Mitsudomi, Tetsuya
    Fukuoka, Masahiro
    Nukiwa, Toshihiro
    CLINICAL CANCER RESEARCH, 2009, 15 (13) : 4493 - 4498
  • [39] The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib
    Buckingham, Lela E.
    Coon, John S.
    Morrison, Larry E.
    Jacobson, Kristine K. B.
    Jewell, Susan S.
    Kaiser, Kelly A.
    Mauer, Ann M.
    Muzzafar, Tariq
    Polowy, Clayton
    Basu, Sanjib
    Gale, Meryl
    Villaflor, Victoria M.
    Bonomi, Philip
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) : 414 - 422
  • [40] Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor
    Lee, H.
    Lee, K.
    Ahn, M.
    Hwang, H.
    Lee, J.
    Park, K.
    Kim, T.
    Yi, C.
    Chung, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345